Study Finds Semaglutide Lower Suicide Ideation Risk Compared to Other Diabetes and Obesity Medications

According to a new federally-funded study by the National Institutes of Health, the drugs semaglutide, commonly used to treat diabetes and obesity, have been found to reduce the risk of suicide ideation in patients compared to other medications used for the same conditions. The study, sponsored by the National Institutes of Health and conducted by researchers from Case Western Reserve University, analyzed electronic medical records of over 1.8 million patients with diabetes or obesity between 2017 and 2022. Of these patients, approximately 240,000 received treatment for obesity or overweight, while nearly 1.6 million received treatment for diabetes.

During a six-month follow-up period, individuals taking semaglutide, had a 49% to 73% lower risk of experiencing suicidal ideation for the first time or recurrently compared to those taking other medications for these conditions. The researchers emphasize the need for closer evaluation of reports concerning suicidal ideation associated with these drugs and recommend longer-term follow-up of patients. It is important to note that the study only considered patients receiving semaglutide or other medications for diabetes or obesity treatment and did not account for the general population's use of semaglutide.

Dr. Rong Xu, one of the co-authors from Case Western Reserve University, highlighted that obesity and diabetes themselves are risk factors for suicidal ideation. However, the study was not designed to determine whether GLP-1 receptor agonists, the class of drugs to which semaglutide belong, reduce these ideations.

This research comes as European and American regulatory agencies investigate individual reports of self-harm ideation in people taking semaglutide, also known as GLP-1 receptor agonists. Last year, the European Medicines Agency (EMA) announced a review of approximately 150 reports possibly related to semaglutide and other GLP-1 receptor agonists. These drugs function by acting on hormones that regulate appetite and satiety in the intestines and the brain, differing from the mechanisms of older weight-loss medications.

The Health Canada and the U.S. Food and Drug Administration are also investigating unconfirmed reports of suicidal ideation or behavior in individuals using GLP-1 receptor agonists.

Since receiving approval for the treatment of obesity in June 2021, semaglutide, marketed as Wegovy, has been taken by millions of people in the United States, rapidly gaining popularity.

A spokesperson from Novo Nordisk, stated that this new study reflects the data collected from large clinical trials and post-marketing surveillance, all of which did not demonstrate a "causal association" between semaglutide and suicidal ideation or self-harm behavior.

While this retrospective observational study cannot prove that GLP-1 receptor agonists do not increase the risk of suicidal ideation, these findings may help alleviate concerns. The researchers were not able to assess the statistical significance of actual suicide attempts, acknowledging that such attempts differ significantly from suicidal ideation.

This study provides new insights into the relationship between GLP-1 receptor agonists and suicidal ideation. However, as a retrospective observational study, there are limitations, and further research is still needed to confirm these results and gain a deeper understanding of the impact of GLP-1 receptor agonists on mental health.

In conclusion, this study highlights one potential benefit of GLP-1 receptor agonist therapy for diabetes and obesity, which is the reduction in the risk of suicidal ideation. Nevertheless, patients using these medications still require close monitoring and guidance from healthcare professionals. Further research and monitoring will contribute to a better understanding of the safety and efficacy of these drugs.